| First Author | Wahle BM | Year | 2018 |
| Journal | Oncotarget | Volume | 9 |
| Issue | 1 | Pages | 718-725 |
| PubMed ID | 29416648 | Mgi Jnum | J:309215 |
| Mgi Id | MGI:6756864 | Doi | 10.18632/oncotarget.22002 |
| Citation | Wahle BM, et al. (2018) Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2. Oncotarget 9(1):718-725 |
| abstractText | Mutations in the tumor suppressor gene NF2 lead to Neurofibromatosis type 2 (NF2), a tumor predisposition syndrome characterized by the development of schwannomas, including bilateral vestibular schwannomas with complete penetrance. Recent work has implicated the importance of COX-2 in schwannoma growth. Using a genetically engineered murine model of NF2, we demonstrate that selective inhibition of COX-2 with celecoxib fails to prevent the spontaneous development of schwannomas or sensorineural hearing loss in vivo, despite elevated expression levels of COX-2 in Nf2-deficient tumor tissue. These results suggest that COX-2 is nonessential to schwannomagenesis and that the proposed tumor suppressive effects of NSAIDs on schwannomas may occur through COX-2 independent mechanisms. |
